Related Experiment Video
Updated: Jun 14, 2025
04:35
Saline Lavage for Sampling of the Canine Nasal Immune Microenvironment
Published on: December 27, 2024
297
MicroRNAs implicated in canine diffuse large B-cell lymphoma prognosis.
Nelly O Elshafie1, Michael Gribskov2, Nathanael I Lichti3
1Department of Comparative Pathobiology, Purdue University, West Lafayette, IN, USA.
FEBS Open Bio
|September 1, 2024
Summary
Specific microRNAs (miRNAs) correlate with outcomes in dogs with diffuse large B-cell lymphoma (DLBCL). Lower expression of miR-192-5p and miR-16-5p indicates longer progression-free survival in canine DLBCL.
Area of Science:
- Veterinary Oncology
- Molecular Biology
- Genetics
Background:
- Diffuse large B-cell lymphoma (DLBCL) is the most common non-Hodgkin lymphoma (NHL) in dogs, mirroring human disease.
- Early treatment initiation is crucial for managing rapid DLBCL progression and achieving remission in dogs.
Purpose of the Study:
- To investigate the association between microRNA (miRNA) expression and progression-free survival (PFS) in dogs diagnosed with DLBCL.
- To identify specific miRNAs that may serve as predictive biomarkers for DLBCL outcomes in canine patients.
Main Methods:
- Analysis of small RNA sequencing (sRNA-seq) data from lymph node samples of 44 dogs with DLBCL.
- Quantitative PCR (qPCR) was used to validate and quantify the expression levels of selected miRNAs.
Main Results:
- A distinct subset of miRNAs was found to be significantly associated with decreased PFS in dogs with DLBCL.
- Downregulation of miR-192-5p and miR-16-5p expression correlated with increased PFS in affected dogs.
Conclusions:
- miRNA profiling shows potential for identifying dogs with DLBCL likely to experience poor treatment outcomes.
- Identifying specific miRNAs linked to canine DLBCL progression could facilitate personalized treatment strategies.
